Development of innovative antimicrobials against pathogens resistant to antimicrobials
Forthcoming
Status as published by the data source.
Expected Outcome:
This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Tackling diseases and reducing disease burden”. To that end, proposals under this topic should aim to deliver results that are directed at, tailored towards and contributing to all the following expected outcomes:
• The scientific and clinical communities have a better understanding of and access to new and innovative products for the treatment of antimicrobial resistant bacteria and fungi, as well as for further clinical investigation.
• Candidate therapies are available to treat patients for antimicrobial resistant bacteria and fungi, increasing therapeutic options for clinical deployment in the fight against Antimicrobial Resistance (AMR). Scope:
The rapid rise of AMR presents a formidable threat to public health, challenging our ability to treat infections that were once easily managed with standard antimicrobials. As pathogens continually adapt and develop resistance to existing drugs, the efficacy of these treatments diminishes, leading to more severe and prolonged illnesses, increased healthcare costs and productivity losses, and higher mortality rates. This escalating crisis underscores an urgent need for viable therapeutic alternatives required to reduce the burden of diseases caused by antibiotic resistance. Innovative solutions are crucial to maintaining effective disease management and safeguarding public health.
Proposals should pursue the development of innovative and effective antibacterial and antifungal agents, including antibody-based therapies, which meet at least one of the four World Health Organization (WHO) innovation criteria[1], namely: i) new chemical class, ii) new target, iii) new mode of action and iv) no evidence of cross-resistance.
This topic contributes to strengthening the Research and Innovation ecosystem within the EU and supports the implementation of the European Medical Countermeasures Strategy[2] and the forthcoming Critical Medicines Act[3].
Proposals under this topic should not pursue the development of phage-therapies.
Applicants should explicitly state in their proposal which of the following pathogens is targeted and the proposed work should address only this specific pathogen. The proposed work should pursue the development of existing therapeutic candidates targeting exclusively one of the following pathogens:
• Carbapenem resistant Acinetobacter baumanii (CRAB)
• Carbapenem-resistant Enterobacterales (CRE) and third-generation cephalosporin-resistant Enterobacterales (C3GRE)
• Carbapenem resistant Pseudomonas aeruginosa
• Methicillin-Resistant Staphylococcus aureus (MRSA)
• (Drug)-resistant Aspergillus fumigatus
• (Drug)-resistant Candida spp Identifying a specific pathogen does not preclude the exploration of these candidates' effects on other bacteria or fungi. Proposals should thus aim to accelerate testing of novel candidates in human trials, diversify and accelerate the global prophylactic and therapeutic research and development portfolio for AMR bacterial and fungal infections, and to strengthen the leading role of the EU in prophylactic and therapeutic research and development.
Proposals should address all the following areas:
• If necessary, finalisation of in-vivo tests in at least one animal model or, if available in humanised immune system animal models, to demonstrate the protective function of the therapeutics deemed sufficient for moving to first clinical trials.
• If requested by regulators as pre-requisite for clinical studies, in-vivo tests in a non-human primate model.
• Production of batches of the most promising antimicrobials candidates according to the Good Manufacturing Practices (GMP)[4].
• In human clinical safety and efficacy studies, demonstrating a clear regulatory pathway for market authorisation. Attention should be paid to critical biological and social factors such as sex, age, ethnicity, disability and vulnerability. Participation of third countries where AMR bacteria and fungi in the proposal are endemic or where outbreaks have occurred or are ongoing is encouraged.
The participation of start-ups, micro, small and medium-sized enterprises (SMEs)[5] is encouraged with the aim of strengthening their scientific and technological foundations, enhancing their innovation potential, and exploring possibilities for commercial exploitation.
All projects funded under this topic are expected to engage with regulatory bodies in a timely manner to ensure adequacy of the actions from a regulatory point of view.
Proposals should advance research by leveraging already existing and emerging state-of-the-art research initiatives such as the co-funded European Partnership on One Health Anti-Microbial Resistance (EUP OHAMR)[6].
Applicants should provide details of their clinical studies[7] in the dedicated annex using the template provided in the submission system. As proposals under this topic are expected to include clinical studies, the use of the template is strongly encouraged.
[1] https://www.who.int/publications/i/item/9789240093461
[2] https://health.ec.europa.eu/health-emergency-preparedness-and-response-hera/preparedness/medical-countermeasures-strategy_en
[3] https://health.ec.europa.eu/publications/proposal-critical-medicines-act_en
[4] https://health.ec.europa.eu/medicinal-products/eudralex/eudralex-volume-4_en
[5] https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32003H0361
[6] https://cordis.europa.eu/project/id/101217154, https://ohamr.eu
[7] Please note that the definition of clinical studies (see introduction to this Work Programme part) is broad and it is recommended that you review it thoroughly before submitting your application.
- Status
- Forthcoming
- Deadline
- (time not stated)
- Opens
- Published
- Total budget
- €44,200,000
- Grant range
- €8,000,000 – €10,000,000
- Country
- European Union (EU-wide)
- Programme
- Horizon Europe (HORIZON)
- Official page
- Open at the source portal
Other calls under Horizon Europe (HORIZON)
- PV based electrification of the economy: Designing & optimising PV systems supporting industrial electrification and promoting participation in electricity markets (EUPI-PV Partnership)
- Advanced TSO control rooms to enhance grid observability, stability and resilience
- Advanced Distribution Management Systems (ADSM) for more efficient and flexible distribution grids
- Community of practice - Data-Driven Decision-Making in Energy
- Industrial processes and equipment for innovative, reliable and scalable tandem technologies (EUPI-PV Partnership)
- Integrated Approaches for Retrofitting Infrastructures with Innovative Energy Storage Technologies
- Demonstration of hydropower technologies for efficient and forward-looking refurbishment of existing hydropower plants
- Delivery of industrial CCUS clusters – Societal Readiness pilot
All calls under this programme
Similar opportunities
- Development of novel small molecule antiviral therapeutics for pathogens with epidemic potential
- Antimicrobial resistance and antibiotic biosynthesis in soils: developing key understanding and counteractive strategies using a One-Health approach
- Personalised approaches to reduce risks from Adverse Drug Reactions due to administration of multiple medications
- Towards commercialization of food systems microbiome solutions
- Development of predictive biomarkers of disease progression and treatment response by using AI methodologies for chronic non-communicable diseases
- Development of monoclonal antibodies to prevent and treat infections from Flaviviruses
Where this came from
- Source document
- https://ec.europa.eu/info/funding-tenders/opportunities/data/topicDetails/horizon-hlth-2027-01-disease-08.json
- Document fingerprint
9772c0cc3a244348(SHA-256, first 16 hex characters)- Retrieved
- First recorded here
What has changed
- url first recorded as https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/horizon-hlth-2027-01-disease-08 on
- currency first recorded as EUR on
- amount_max first recorded as 10000000.00 on
- amount_min first recorded as 8000000.00 on
- budget_total first recorded as 44200000.00 on
- deadline first recorded as 2027-04-13 on
- opens_on first recorded as 2027-02-10 on
- published_on first recorded as 2025-12-12 on
- status_basis first recorded as source_status on
- status first recorded as forthcoming on
- title first recorded as Development of innovative antimicrobials against pathogens resistant to antimicrobials on
Data source
© European Union, 2026. Source: EU Funding & Tenders Portal. Reused under Commission Decision 2011/833/EU — CC BY 4.0.
Retrieved from the source on .
The source last updated this document on Mon, 02 Mar 2026 09:39:07 GMT.
Personal data of natural persons has been dissociated by quiescence.eu.
This service is not affiliated with, sponsored or endorsed by the data publishers.